Copay Assistance for Expensive Drugs: A Helping Hand That Raises Costs
Copy assistance programs may seem to benefit public health and lower the costs of drugs, but they actually raise the costs of health care in the future.
Originally published on 12/20/2016 in Annals of Internal Medicine
Dr. Bach, along with lead author Dr. Peter Ubel of Duke-Margolis Center for Health Policy, published a piece in Annals of Internal Medicine arguing that drug company copay and coupon programs actually play a significant role in keeping prescription drug costs in the U.S. high.
Many drug manufacturers point to these programs to help patients afford drugs but Bach and Ubel outline why the programs mask underlying costs and what policymakers can do to fix it.
Read the full article here.